A study analysing efficacy and safety of lenvatinib for treatment of hepatocellular carcinoma in the real-world
Latest Information Update: 19 Jul 2021
At a glance
- Drugs Lenvatinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms HCC CHORD; REFLECT
- 08 Jun 2021 Results (July 2018 to December 2019 ; n= 173) evaluating the starting dose or dose-intensity of Lenvatinib affects survival of patients, presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 01 Mar 2021 New trial record
- 17 Jan 2021 Results presented at the 2021 Gastrointestinal Cancers Symposium